anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a liposome for the oral administration, by incorporating a steryl glucoside and steryl glucoside monopalmitate as active constituents with a phospholipid, etc. CONSTITUTION:One or two or more types of steryl glucoside, e.g. beta-sitosteryl-beta- D-glucoside, and steryl glucoside monopalmitate, as main drugs are added to chloroform containing a phospholipid, e.g. lecithin or sphingolipid phosphoglyceride, dissolved therein, and if necessary a membrane stabilizer, e.g. cholesterol, or a charging agent is added thereto, and dissolved therein. The chlorofrom is then distilled away, and a buffering agent, etc. is then added to give a liposome. The ratio between the main drugs and the lipid component as follows: based on one pts.wt. main drugs is 1-10pts.wt. phospholipid, 0.1-5pts.wt. sterol and 0.05-0.5pts.wt. charging agent. EFFECT:Intravenously administrable and easily sterilized under heating. USE:An injection adaptable to the remedy in the region of the hemostasis, reinforcing the blood vessel and antishock.
Autologous dendritic cells loaded with tumor associated antigens from a short-term cell culture of autologous tumor cells. AV-GBM-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
PURPOSE:To provide the title agent, also effective for relieving fatigue due to passive uneasiness, comprising a low-molecular peptide composition obtained by hydrolysis of protein using an enzyme. CONSTITUTION:The objective fatigue-relieving agent comprising a low-molecular peptide composition 200-550 in average molecular weight which can be obtained by hydrolysis at 40-60 deg.C for 18-48hr of protein derived from animals, plants or microorganisms (pref. lactoprotein or soybean protein) using an enzyme (pref. endoprotease active in neutral pH region). This composition consists mainly of dipeptides and tripeptides containing <=20wt.% of peptides with a molecular weight of >=700 and also containing <=5wt.% of free amino acids. The present agent is effective for relieving fatigue due to passive uneasiness as well as active exercise.
CLARITHROMYCIN: daily orally administration in cycles of 28 days; 500mg film-coated tablets LENALIDOMIDE: every cycle of treatment lasts 28 days; daily orally administration is of 21 consecutive days with a week of rest. 20mg capsule hard. The maximum treatment duration is 12 months.
PURPOSE:To obtain a powdery royal jelly having good keeping quality and handleability without causing muddiness and precipitate by subjecting an aqueous alkali solution of royal jelly to coagulate protein and separating and removing the coagulated protein by controlling pH, temperature and concentration of alcohol added. CONSTITUTION:An alkali such as sodium carbonate, normally 15-20% aqueous solution thereof is added to 100 pts.wt. royal jelly at an amount of 0.05-0.15 pts.wt. and the mixture is homogenized using a homogenizer. 95-105 pts.wt. water is added thereto to dilute the mixture and the mixture is controlled to <=pH3 by hydrochloric acid, etc. The ethanol is added to the mixture so as to become 70-80w/w% ethanol concentration and the mixture is heated at 45-55 deg.C for about 15-30min and the main ingredient is extracted into the solution while coagulating protein. Then the mixture containing the coagulated protein is cooled to <=30 deg.C and controlled to pH5.0-5.4, the ethanol concentration is controlled to >=50w/w% and the coagulated protein is eliminated. Then a vehicle such as water soluble dextrin (having >=50wt.% solid content) is added thereto and subjected to freeze-drying to provide the powdery royal jelly for drink.
A pharmaceutical composition effective for preventing and alleviating bronchoconstriction, allergy(ies) and/or inflammation comprises a surfactant and a nucleic acid comprising an oligonucleotide anti-sense to an adenosine A1, A2a, A2b or A3 receptor gene, mRNA, flanking regions or regions bridging the intro/exon borders, analogues which bind thymidine but have low adenosine content or exhibit lower or no adenosine receptor agonist activity, combinations thereof, physiologically acceptable salts thereof or mixtures thereof, and optionally a carrier and other agents such as therapeutic agents and formulation products known in the art. The composition is formulated for administration by a multiplicity of routes for the prevention or alleviation of diseases and conditions associated with breathing difficulties, impeded and obstructed airways, bronchoconstriction, allergy and/or inflammation. Among the appplications of this technology are the prevention and treatment of diseases and conditions such as asthma, kidney damage or failure, ARDS, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), and cancers such as leukemias, lymphomas, carcinomas, and the like, e.g. colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic, lung, breast, and prostate metastases, etc., to counter the renal damage and failure associated with ischemic conditions and the administration of certain drugs and radio active diagnostic and therapeutic agents, as well as a joint therapy with the administration of adenosine and adenosine-like agents in the treatment of arrhythmias such as SVT and in cardiovascular function tests (stress tests). The present agent(s) is (are) also suitable for administration before, during and after other treatments, including radiation, chemotherapy, antibody therapy, phototherapy and cancer, and other types of surgery. Alternatively, the present agent may be effectively administered preventatively, prophylactically or therapeutically, and in conjunction with other therapies, or by itself for conditions without known therapies or as a substitute for therapies that have significant negative side effects.
INTRODUCTION: Four-dimensional (4D) intracardiac echocardiography (ICE) is a novel cardiac imaging modality that has been applied to various workflows, including catheter ablation, tricuspid valve repair, and left atrial appendage occlusion (LAAO). The use of this type of advanced ICE imaging may ultimately allow for the replacement of transesophageal echocardiography (TEE) for LAAO, providing comparable imaging quality while eliminating the need for general anesthesia.
METHODS: Based on our initial clinical experience with 4D ICE in LAAO, we have developed an optimized workflow for the use of the NUVISION™ 4D ICE Catheter in conjunction with the GE E95 and S70N Ultrasound Systems in LAAO. In this manuscript, we provide a step-by-step guide to using 4D ICE in conjunction with compatible imaging consoles. We have also evaluated the performance of 4D ICE with the NUVISION Ultrasound Catheter versus TEE in one LAAO case and present those results here.
RESULTS: In our comparison of 4D ICE using our optimized workflow with TEE in an LAAO case, ICE LAA measurements were similar to those from TEE. The best image resolution was seen via ICE in 2-dimensional and multislice modes (triplane and biplane). The FlexiSlice multiplanar reconstruction tool, which creates an en-face image derived from a 4D volume set, also provided valuable information but yielded slightly lower image quality, as expected for these volume-derived images. For this case, comparable images were obtained with TEE and ICE but with less need to reposition the ICE catheter.
CONCLUSION: The use of optimized 4D ICE catheter workflow recommendations allows for efficient LAAO procedures, with higher resolution imaging, comparable to TEE.
PROBLEM TO BE SOLVED: To obtain a salt dentifrice composition exhibiting massage effect due to friction between gums and effective for treating and preventing periodontal diseases without excessively irritating gum and impairing damage in brushing tooth. SOLUTION: This salt dentifrice composition contains >=5wt.% globular common salt having 0.1-1mm particle diameter. The globular common salt close to true globe is obtained by bringing usual dice-like cubic sodium chloride particles having 0.01-1mm particle diameter into contact with blaze or a high- temperature gas, heated to >=800 deg.C, preferably 1,000-1,300 deg.C for >=0.1sec., carrying out sphering by partial melting of salt particles and surface tension of particles and cooling and solidifying the particles. The interior of particles is free from gap and has a glass-like dense shape consisting of a monosilic single structure. The globular particles, etc., are properly blended with a conventional components as other components and the blend is prepared as uniform and paste-like toothpaste.  The composition is effective in preventing and treating periodontal diseases such as gingivitis or blennorrhoea alveolaris.
<P>PROBLEM TO BE SOLVED: To provide a powdery material in which time dependent optical characteristics are difficultly changed by compensating defects inherited to titanium dioxide imparting unnaturally smooth make up finish.  <P>SOLUTION: The powdery material is provided by coating a titanium dioxide-coated platy powder material with silica and/or alumina and hydroxyapatite. As the platy powdery material, one or more species selected from talc, sericite and mica are preferable. The constitutional mass ratio is preferably 45-70 mass% platy powdery material, 7-12 mass% titanium dioxide, 20-27 mass% silica and alumina and 1-7 mass% hydroxyapatite. The powdery material preferably has a five-layered structure prepared by coating the platy powdery material one by one with titanium oxide, alumina, silica and hydroxyapatite in this order. The powdery material is preferably brought to be contained in makeup cosmetics or UV-preventive cosmetics. The cosmetics are preferably solid powdery cosmetics used in summer.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
A method is provided for controlling exchange of privacy sensitive data between a first certified party server (A) associated with a first party and at least a second certified party server (B) associated with a second party using a certified intermediate server (Y) subject to authorizations (X AB ) imposed by an authorizing party (X), using a public network. Therein the first certified party server (A) transmits (S 2 ) to the certified intermediate server (Y) a primary request (ARQ(I xA ,Γ xA )) that includes a digitally signed primary request indication (I XA ,Γ XA ) comprising a primary request indication (I XA ) specifying a set of privacy sensitive data units (X A ) for which a copy (C XA ) is requested and a digital signature (Γ XA ) of said first party, associated with said primary request indication (I XA ). The certified intermediate server (Y) determines (S 3 ) which authorizations are provided by the authorizing party (X) for transmission of information concerning privacy sensitive data r from the second certified second party server (B) to the first certified party server (A). The certified intermediate server (Y) executes (S 4 ) a query procedure (QP) in which at least includes transmitting the digitally signed primary request (I XA ,Γ XA ) by the certified intermediate server (Y) to the second certified party server (B). The second certified party server (B) inspects (S 5 ) the digital signature (Γ XA ) to verify authenticity of said the primary request. Subject to confirmation of its authenticity it makes available a provider copy (C XAMB ) including at least a censored copy, being a copy of a censored subset of privacy sensitive data units, the censored subset comprising the privacy sensitive data units as specified by the primary request indication (I xA ) subject at least to said authorizations (X AB ) and subject to availability thereof with the at least a second certified party server. It also provides a second party digital signature, i.e. a digital signature (Γ B ) of the second certified party, associated with the censored subset. Upon completion of the query procedure, the censored copy and the second party digital signature are made available to the first certified party server as a digitally signed authorized copy.
The invention belongs to the field of platelet medicines, and discloses application of a protein kinase A inhibitor in preparation of a medicine for treating diseases related to platelet increase. The invention discusses the function of protein kinase A in the process of regulating and controlling platelet apoptosis through experiments for the first time. The research proves that the inhibition of the activity of the protein kinase A can cause the occurrence of the apoptosis of endogenous platelets, which indicates that the protein kinase A inhibitor has the function of promoting the apoptosis of platelets, and the protein kinase A regulates the apoptosis of platelets by regulating the phosphorylation of serine at the BAD 155 site. Inhibitors of protein kinase a can cause platelet apoptosis in vitro experiments and a decrease in platelet counts in vivo in experimental animals in vivo experiments. The number of circulating blood platelets in the mice with the protein kinase A gene knocked out is reduced. Therefore, the inhibitor of the protein kinase A has the potential of being developed into a novel medicine for treating the thrombocythemia diseases, and has scientific research and economic values.
BACKGROUD: The recurrence rate of chronic rhinosinusitis with nasal polyps (CRSwNP) is positively correlated with eosinophil infiltration. Increased interleukin (IL)-19 and eosinophil chemokine RANTES levels have been reported in patients with CRSwNP. This study aimed to clarify the role of IL-19 in mediating RANTES expression and eosinophilic infiltration in eosinophilic CRSwNP (Eos CRSwNP).
METHODS: Nasal tissue samples were obtained from patients with CRSwNP and controls. The expression of IL-19, its receptors, ECP, and RANTES in tissues was investigated. Primary human nasal epithelial cells (HNECs) and nasal polyp tissue blocks were cultured, then stimulated by IL-19; ERK phosphorylation, NF-κB pathway activation, RANTES level, eosinophils migration and infiltration were detected using RT-qPCR, ELISA, western blotting, HE, immunohistochemistry, immunofluorescence staining, confocal microscopy, and transwell migration assay.
RESULTS: The expression of IL-19 and its receptors (IL-20R1/IL-20R2), eosinophil cationic protein, and RANTES in nasal tissues from patients with Eos CRSwNP was significantly increased compared to that in non-Eos CRSwNP and control subjects. IL-19 co-localized with RANTES in nasal tissues and significantly elevated RANTES expression in HNECs. IL-19-blocking antibody and siRNA knockdown of IL-20R1 ameliorated the effect of IL-19 on RANTES secretion in HNECs. Moreover, IL-19-induced RANTES upregulation was associated with the activation of the ERK and NF-κB pathways. NF-κB activation was mediated by the ERK pathway in IL-19-treated HNECs, and IL-19 enhanced eosinophil infiltration in nasal polyp tissue blocks.
CONCLUSIONS: Our findings indicate that IL-19 promotes RANTES expression via the ERK/NF-κB pathway in HNECs and is implicated in eosinophil infiltration in patients with Eos CRSwNP.
Number of participant is 16. In addition to the conventional therapy, SNAGs technique was applied.
Apparatus and methods for calculating cardiac output (CO) of a living subject using applanation tonometry measurements. In one embodiment, the apparatus and methods build a nonlinear mathematical model to correlate physiologic source data vectors to target CO values. The source data vectors include one or more measurable or derivable parameters such as: systolic and diastolic pressure, pulse pressure, beat-to-beat interval, mean arterial pressure, maximal slope of the pressure rise during systole, the area under systolic part of the pulse pressure wave, gender (male or female), age, height and weight. The target CO values are acquired using various methods, across a plurality of individuals. Multidimensional nonlinear optimization is then used to find a mathematical model which transforms the source data to the target CO data. The model is then applied to an individual by acquiring physiologic data for the individual and applying the model to the collected data.
Ischemic stroke is a dreadful vascular disorder that poses enormous threats to the public health. Due to its complicated pathophysiological features, current treatment options after ischemic stroke attack remains unsatisfactory. Insufficient drug delivery to ischemic lesions impeded by the blood-brain barrier (BBB) largely limits the therapeutic efficacy of most anti-stroke agents. Herein, inspired by the rapid BBB penetrability of 4T1 tumor cells upon their brain metastasis and natural roles of platelet in targeting injured vasculatures, a bio-derived nanojacket is developed by fusing 4T1 tumor cell membrane with platelet membrane, which further clothes on the surface of paeonol and polymetformin-loaded liposome to obtain biomimetic nanoplatforms (PP@PCL) for ischemic stroke treatment. The designed PP@PCL could remarkably alleviate ischemia-reperfusion injury by efficiently targeting ischemic lesion, preventing neuroinflammation, scavenging excess reactive oxygen species (ROS), reprogramming microglia phenotypes, and promoting angiogenesis due to the synergistic therapeutic mechanisms that anchor the pathophysiological characteristics of ischemic stroke. As a result, PP@PCL exerts desirable therapeutic efficacy in injured PC12 neuronal cells and rat model of ischemic stroke, which significantly attenuates neuronal apoptosis, reduces infarct volume, and recovers neurological functions, bringing new insights into exploiting promising treatment strategies for cerebral ischemic stroke management.
PURPOSE: Bladder outlet obstruction (BOO) is common in older adults. Many older adults who pursue surgery have additional vulnerabilities affecting surgical risk, including frailty. A clinical tool that builds on frailty to predict surgical outcomes for the spectrum of BOO procedures would be helpful to aid in surgical decision-making but does not currently exist.
MATERIALS AND METHODS: Medicare beneficiaries undergoing BOO surgery from 2014 to 2016 were identified and analyzed using the Medicare MedPAR, Outpatient, and Carrier files. Eight different BOO surgery categories were created. Baseline frailty was calculated for each beneficiary using the Claims-Based Frailty Index (CFI). All 93 variables in the CFI and the 17 variables in the Charlson Comorbidity Index were individually entered into stepwise logistic regression models to determine variables most highly predictive of complications. Similar and duplicative variables were combined into categories. Calibration curves and tests of model fit, including C statistics, Brier scores, and Spiegelhalter P values, were calculated to ensure the prognostic accuracy for postoperative complications.
RESULTS: In total, 212,543 beneficiaries were identified. Approximately 42.5% were prefrail (0.15 ≤ CFI < 0.25), 8.7% were mildly frail (0.25 ≤ CFI < 0.35), and 1.2% were moderately-to-severely frail (CFI ≥0.35). Using stepwise logistic regression, 13 distinct prognostic variable categories were identified as the most reliable predictors of postoperative outcomes. Most models demonstrated excellent model discrimination and calibration with high C statistic and Spiegelhalter P values, respectively, and high accuracy with low Brier scores. Calibration curves for each outcome demonstrated excellent model fit.
CONCLUSIONS: This novel risk assessment tool may help guide surgical prognostication among this vulnerable population.
Stenotrophomonas maltophilia was considered to be a low-virulence organism. But it has emerged as a prominent opportunistic pathogen in patients with certain risk factors. This study aimed to describe an outbreak experienced in our hospital with all dynamics while evaluating previous S. maltophilia outbreak reports. S. maltophilia isolates were obtained from a university hospital in Türkiye in a seven-months period. Antimicrobial resistance, type of infections, predisposing factors of infected patients, antibiotic therapy, outcome of infections, and outbreak source were investigated. Also, S. maltophilia outbreaks in the literature were reviewed. In the 12 months prior to the outbreak, prevalence rate of clinical samples including S. maltophilia was 7/1,000 patient per day, opposed to 113/1,000 patient per day during the outbreak. Although a large number of cases were observed in a short seven-month period, a source of contamination could not be detected. Stable mortality rates (or remaining close to the average) during outbreaks can be attributed to the careful attention paid by laboratory and clinic physicians during procedures. S. maltophilia has potential to spread outbreaks and infect patients in operating rooms and intensive care units during invasive procedures.
INTRODUCTION: Atrial fibrillation (AF) is associated with an elevated risk of cognitive impairment and dementia. Understanding the cognitive sequelae and brain structural changes associated with AF is vital for addressing ensuing health care needs.
METHODS AND RESULTS: We examined 1335 stroke-free individuals with AF and 2683 matched controls using neuropsychological assessments and multimodal neuroimaging. The analysis revealed that individuals with AF exhibited deficits in executive function, processing speed, and reasoning, accompanied by reduced cortical thickness, elevated extracellular free-water content, and widespread white matter abnormalities, indicative of small vessel pathology. Notably, brain structural differences statistically mediated the relationship between AF and cognitive performance.
DISCUSSION: Integrating a comprehensive analysis approach with extensive clinical and magnetic resonance imaging data, our study highlights small vessel pathology as a possible unifying link among AF, cognitive decline, and abnormal brain structure. These insights can inform diagnostic approaches and motivate the ongoing implementation of effective therapeutic strategies. Highlights We investigated neuropsychological and multimodal neuroimaging data of 1335 individuals with atrial fibrillation (AF) and 2683 matched controls. Our analysis revealed AF-associated deficits in cognitive domains of attention, executive function, processing speed, and reasoning. Cognitive deficits in the AF group were accompanied by structural brain alterations including reduced cortical thickness and gray matter volume, alongside increased extracellular free-water content as well as widespread differences of white matter integrity. Structural brain changes statistically mediated the link between AF and cognitive performance, emphasizing the potential of structural imaging markers as a diagnostic tool in AF-related cognitive decline.
Healthy patients aged 18-50 who have a uterus, identify as female and have come to the outpatient Center for Women's Health (CWH) for management of bleeding, pelvic pain and fibroids. They will be offered enrollment post-surgery or procedure and will be followed longitudinally for 12 months.